Infliximab and Basiliximab for Treatment of Steroid Refractory acute Graft Versus Host Disease
To estimate the CR rate by 28 days after starting study drugs, without additional therapy for patients with steroid refractory aGvHD.
Keywordssteroid, refractory, aGvHD, Infliximab, Basiliximab
Principal InvestigatorLamis Eldjerou, M.D.
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.